Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

September 1, 2025

Study Completion Date

December 19, 2025

Conditions
InfectionsObesity and Obesity-related Medical Conditions
Interventions
DRUG

Piperacillin-tazobactam administered in a prolonged infusion

For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.

DRUG

Piperacillin-tazobactam administered in a standard infusion

For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)

Trial Locations (1)

J4V 2H1

Hôpital Charles- Le Moyne, Greenfield Park

All Listed Sponsors
lead

CR-CSSS Champlain-Charles-Le Moyne

OTHER

NCT06690905 - Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity | Biotech Hunter | Biotech Hunter